Мађарска - Мађарски - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

genera inc. - fertozo bursitis vírusa (gumboroi betegség vírusa, ibdv) - liofilizátum - avian infectious bursal disease virus vaccine (gumboro disease) - házityúk

Европска Унија - Мађарски - EMA (European Medicines Agency)

ucb pharma s.a. - lakozamidot - epilepszia, részleges - antiepileptikumok, - lakozamid ucb az monoterápiában, illetve kiegészítő terápia a kezelés parciális görcsrohamok-vagy anélkül másodlagos általánosítás a felnőttek, kamaszok, a gyerekek 4 éves kor epilepszia.

Европска Унија - Мађарски - EMA (European Medicines Agency)

equicord s.l. - lovak köldökzsinór mesenchymalis őssejtek - egyéb gyógyszerek az izom-csontrendszer rendellenességeihez - lovak - csökkentése sántaság társul enyhe vagy mérsékelt degeneratív ízületi betegség (osteoarthritis) a lovakat.

Мађарска - Мађарски - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

genera inc. - fertozo bronchitis vírusa (ibv) - liofilizátum szuszpenziós injekcióhoz - avian infectious bronchitis virus vaccine - házityúk

Мађарска - Мађарски - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

genera inc. - fertozo bursitis vírusa (gumboroi betegség vírusa, ibdv) - liofilizátum - avian infectious bursal disease virus vaccine (gumboro disease) - házityúk

Европска Унија - Мађарски - EMA (European Medicines Agency)

nova laboratories ireland limited - azatioprin - graft visszautasítás - immunszuppresszánsok - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Европска Унија - Мађарски - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunszuppresszánsok - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Европска Унија - Мађарски - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - pikkelysömör - immunszuppresszánsok - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Европска Унија - Мађарски - EMA (European Medicines Agency)

extrovis eu ltd. - lakozamidot - epilepszia - antiepileptikumok, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Мађарска - Мађарски - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

roche magyarország kft. - tenoxicam -